Skip to main
CVRX

CVRx (CVRX) Stock Forecast & Price Target

CVRx (CVRX) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CVRx is off to a strong start in 2026 with Q1 revenue growth and GM both ahead of the company's guidance for the year. Its proprietary Barostim technology and the expansion of its TAM through the BENEFIT-HF trial could potentially lead to increased sales and revenue in the future. However, CVRx's heavy reliance on a single product and market, as well as the need for continued physician and patient marketing and adequate reimbursement, present potential risks.

Bears say

CVRx is a medical device company with a proprietary platform technology, Barostim, that addresses cardiovascular diseases by leveraging the power of the brain. Despite optimism around the company's growth, its current revenue is still primarily derived from the US market and is heavily reliant on sales productivity and steady adoption of Barostim therapy. Additionally, while the recent Category I CPT code and increased facility with Innovatus Capital Partners provide some financial stability in the short term, there are still potential risks of dilution and challenges with payer approvals that could impact future growth.

CVRx (CVRX) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CVRx (CVRX) Forecast

Analysts have given CVRx (CVRX) a Buy based on their latest research and market trends.

According to 2 analysts, CVRx (CVRX) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CVRx (CVRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.